HONG KONG – Taigen Biotechnology Co. Ltd. started the first clinical trials of its stem cell mobilizer drug, burixafor (TG-0054), in mainland China. It received regulatory clinical trial approval from the CFDA in 2013 for phase I and II trials as a chemotherapy sensitizer in combination with two chemotherapeutic agents for the treatment of leukemia.